Incyte Executives Buy Big—CMO’s $44,000‑Share Purchase Signals Bullish Pipeline Confidence
Insider buying by Incyte’s CMO signals confidence in its late‑stage pipeline and suggests a potential rally for investors.
3 minutes to read
INCYTE CORP
Cagnoni’s New Share Swings: Buying at a Discount, Selling at the Peak—Is Incyte on the Verge of a Breakout?
Insider buying at Incyte signals confidence in its oncology pipeline – see why Cagnoni’s trades suggest a bullish outlook.
3 minutes to read
Incyte Exec Trotta Sells 537 Shares, Signals Routine Liquidity Move Amid New R&D Leadership Shake‑Ups
Trotta Matteo’s 537‑share sale shows routine liquidity, not a warning: insider buys and new leadership signal Incyte’s growing confidence and future upside.
3 minutes to read
Incyte Exec Heeson Lee Sells 111 Shares in Routine Portfolio Move, Company Shares Surge 1.4% Amid Positive EMA Outlook
Heeson Lee’s small February sale of Incyte shares shows disciplined insider trading amid the company’s steady growth and solid oncology pipeline.
3 minutes to read
Incyte EVP’s Jan. 6 Share Sale: A Routine Tax Move Amid Explosive Oncology Momentum
Incyte insider sale: EVP Issa Khairie’s January 2026 tax‑related share sale shows routine trading, not a confidence dip, amid strong oncology pipeline growth.
3 minutes to read
Incyte CMO’s Routine Share Sale Signals No Threat to Monjuvi Momentum, Analysts Say
Incyte insider sale by EVP Steven H. Stein shows disciplined portfolio moves, not a warning, amid Monjuvi success and strong growth prospects.
3 minutes to read